Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
02 nov. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of...
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
31 oct. 2023 07h30 HE
|
Repligen Corporation
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 millionOrders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to...
Repligen to Report Third Quarter 2023 Financial Results
17 oct. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2023 financial results on Tuesday, October 31,...
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
02 oct. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed...
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
26 sept. 2023 07h30 HE
|
Repligen Corporation
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applicationsExpands Repligen’s Fluid Management portfolio, complements single-use bag...
Repligen Appoints Jason K. Garland as Chief Financial Officer
12 sept. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed...
Repligen Corporation to Present at Wells Fargo Healthcare Conference
01 sept. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
17 août 2023 08h00 HE
|
Repligen Corporation
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementationCustomers experience optimized facility equipment...
Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
02 août 2023 07h30 HE
|
Repligen Corporation
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full year revenue guidance to range of $635-$665...
Repligen to Report Second Quarter 2023 Financial Results
19 juil. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2023 financial results on Wednesday, August 2,...